Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine long-term safety in adult ADHD
NCT00969618Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Nov 2009; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00969618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00969618.